A 2018 study suggested that the combination of lumacaftor (VX-809) + ivacaftor (VX-770) improved wound repair rates and transepithelial resistance in primary epithelial cell cultures from CF donors with CFTR trafficking mutations (Adam et al., 2018). This evidence concerns the gene CFTR and cystic fibrosis.